Tag: Semaglutide

Ajanta Pharma mentioned it has signed an in-licensing settlement with Biocon to market semaglutide, a GLP-1 receptor agonist, throughout 26 nations spanning Africa, the Center East and Central Asia, as Indian drugmakers sharpen their concentrate on advanced diabetes therapies in rising markets.  Underneath the settlement, Biocon will provide semaglutide to Ajanta for unique advertising in…